Article info

Original research
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Authors

  1. Correspondence to Dr Hua Zhang; hua.zhang{at}nyulangone.org; Dr Kwok-Kin Wong; kwok-kin.wong{at}nyulangone.org
View Full Text

Citation

Pan Y, Hao Y, Han H, et al
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Publication history

  • Accepted July 28, 2022
  • First published September 8, 2022.
Online issue publication 
September 08, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.